Opus Genetics: Chardan Capital keeps Buy rating, raises PT to $9.

jueves, 13 de noviembre de 2025, 8:50 am ET1 min de lectura
IRD--

Opus Genetics: Chardan Capital keeps Buy rating, raises PT to $9.

Opus Genetics: Chardan Capital keeps Buy rating, raises PT to $9.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios